NASDAQ:PGNX

Progenics Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$4.10
0.00 (0.00 %)
(As of 06/19/2020)
Add
Compare
Today's Range
$3.94
$4.79
50-Day Range
$4.10
$4.10
52-Week Range
$1.89
$6.37
Volume34.93 million shs
Average Volume1.16 million shs
Market Capitalization$355.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Progenics Pharmaceuticals logo

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.98 out of 5 stars

Medical Sector

1143rd out of 2,100 stocks

Pharmaceutical Preparations Industry

522nd out of 830 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What stocks does MarketBeat like better than Progenics Pharmaceuticals?

Wall Street analysts have given Progenics Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Progenics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative trailing twelve-month return on equity of 129.46%.
View Progenics Pharmaceuticals' earnings history
.

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the following people:
  • Mr. Mark R. Baker, CEO & Director (Age 64)
  • Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
  • Mr. Benedict Osorio, Chief Operating Officer (Age 62)
  • Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
  • Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)

Who are some of Progenics Pharmaceuticals' key competitors?

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), IMAX (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), OPKO Health (OPK), Citius Pharmaceuticals (CTXR) and Dynavax Technologies (DVAX).

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $4.10.

How much money does Progenics Pharmaceuticals make?

Progenics Pharmaceuticals has a market capitalization of $355.05 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Progenics Pharmaceuticals have?

Progenics Pharmaceuticals employs 79 workers across the globe.

What is Progenics Pharmaceuticals' official website?

The official website for Progenics Pharmaceuticals is www.progenics.com.

Where are Progenics Pharmaceuticals' headquarters?

Progenics Pharmaceuticals is headquartered at ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.